Though bevirimat had particular challenges, in that people who had resistance to protease inhibitors were less likely to benefit from the drug, the company said it had at least one backup compound if bevirimat proved ineffective.
It is unclear whether Myriad will sell these compounds to another company for further development.
Myriad had been developing a maturation inhibitor called bevirimat (MPC-4326, PA-457) since 2009, after purchasing the rights to the drug from Panacos PANC Pharmaceuticals
Looking further, but recent movement is not about the drug bevirimat.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.